Role of surgery in high-risk localized prostate cancer

Current Oncology

Volumn 17, Issue SUPPL. 2, 2010, Pages

  Lawrentschuk, Nathan ^a,b   Trottier, G ^a,b   Kuk, C ^a,b   Zlotta, A R ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Outcomes; Pathology; Prostate neoplasm; Prostatectomy

Indexed keywords

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC ERROR; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COUNSELING; PELVIS LYMPHADENECTOMY; POSTOPERATIVE COMPLICATION; PROSTATE CANCER; QUALITY OF LIFE; RADICAL RETROPUBIC PROSTATECTOMY; RECURRENCE RISK; RISK BENEFIT ANALYSIS; RISK FACTOR; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 78149443866     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i0.705     Document Type: Article

References (44)

1. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
2. Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer 2002;95:2302-7.
3. Moon TD, Brawer MK, Wilt TJ. Prostate Intervention Versus Observation Trial (pivot): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. pivot Planning Committee. J Natl Cancer Inst Monogr 1995;:69-71.
4. Donovan J, Hamdy F, Neal D, et al. Prostate Testing for Cancer and Treatment (protect) feasibility study. Health Technol Assess 2003;7:1-88.
5. Montie JE. Initial therapy with radical prostatectomy for high risk localized prostate cancer. J Urol 2006;176:S27-9.
6. Joniau S, Hsu CY, Lerut E, et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007;51:388-94.
7. Heidenreich A, Aus G, Bolla M, et al. eau guidelines on prostate cancer. Eur Urol 2008;53:68-80.
8. Lavery HJ, Nabizada-Pace F, Carlucci JR, Brajtbord JS, Samadi DB. Nerve-sparing robotic prostatectomy in preoperatively high-risk patients is safe and efficacious. Urol Oncol 2010;:. [Epub ahead of print]
9. Spahn M, Weiss C, Bader P, et al. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation. Urol Int 2010;84:164-73.
10. Zlotta AR, Trottier G, Van Rhijn B, et al. Nerve-sparing radical prostatectomy in selected high-risk and locally advanced prostate cancers is associated with low positive margin rates using a combination of preoperative mri, special instrumentation and intra-operative frozen sections [abstract]. Eur Urol 2010;2(suppl):226.
11. Ham WS, Park SY, Rha KH, Kim WT, Choi YD. Robotic radical prostatectomy for patients with locally advanced prostate cancer is feasible: results of a single-institution study. J Laparoendosc Adv Surg Tech A 2009;19:329-32.
12. Shikanov SA, Thong A, Gofrit ON, et al. Robotic laparoscopic radical prostatectomy for biopsy Gleason 8 to 10: prediction of favorable pathologic outcome with preoperative parameters. J Endourol 2008;22:1477-81.
13. Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC. Radical prostatectomy for clinical stage T3a disease. Cancer 2007;109:1273-8.
14. Bastian PJ, Gonzalgo ML, Aronson WJ, et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006;107:1265-72.
15. Donohue JF, Bianco FJ Jr, Kuroiwa K, et al. Poorly differentiated prostate cancer treated with radical prostatectomy: longterm outcome and incidence of pathological downgrading. J Urol 2006;176:991-5.
16. Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 2006;176:564-8.
17. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005;95:751-6.
18. Manoharan M, Bird VG, Kim SS, Civantos F, Soloway MS. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/= 8. BJU Int 2003;92:539-44.
19. Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 2000;38:372-9.
20. van den Ouden D, Hop WC, Schröder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998;160:1392-7.
21. Gerber GS, Thisted RA, Chodak GW, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997;32:385-90.
22. Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 1995;154:1447-52.
23. Van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008;53:253-9.
24. Futterer JJ. mr imaging in local staging of prostate cancer. Eur J Radiol 2007;63:328-34.
25. Silberstein JL, Derweesh IH, Kane CJ. Lymph node dissection during robot-assisted radical prostatectomy: where do we stand? Prostate Cancer Prostatic Dis 2009;12:227-32.
26. Briganti A, Blute ML, Eastham JH, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009;55:1251-65.
27. Burkhard FC, Schumacher MC, Studer UE. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated. Nat Clin Pract Urol 2006;3:454-5.
28. Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: eortc 22911. J Clin Oncol 2007;25:4178-86.
29. Wiegel T, Bottke D, Steiner U, et al. Phase iii postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: aro 96-02/ auo ap 09/95. J Clin Oncol 2009;27:2924-30.
30. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956-62.
31. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (eortc trial 22911). Lancet 2005;366:572-8.
32. McVey GP, Parker C. Adjuvant vs. salvage radiotherapy for pathologically advanced prostate cancer. Curr Opin Urol 2010;20:229-33.
33. Schröder FH, Kurth KH, Fossa SD, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009;55:14-22.
34. Engel J, Bastian PJ, Baur H, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010;:. [Epub ahead of print]
35. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 2002;20:3199-205.
36. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (spcg-7/sfuo-3): an open randomised phase iii trial. Lancet 2009;373:301-8.
37. Studer UE, Collette L, Sylvester R. Can radical prostatectomy benefit patients despite the presence of regional metastases? Eur Urol 2010;:. [Epub ahead of print]
38. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-9.
39. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9.
40. Sanderson KM, Penson DF, Cai J, et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol 2006;176:2025-31.
41. Strope SA, Coelho M, Wood DP, Hollenbeck BK. Robotassisted salvage prostatectomy: evaluation of initial patientreported outcomes. J Endourol 2010;24:425-7.
42. Bianco FJ Jr, Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:448-53.
43. Oh RJ, Yoshioka Y, Tanaka E, et al. High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: results of a retrospective analysis. Radiat Med 2006;24:58-64.
44. Lepor H. Selecting treatment for high-risk, localized prostate cancer: the case for radical prostatectomy. Rev Urol 2002;4:147-52.